481 related articles for article (PubMed ID: 28017259)
1. Zotarolimus-eluting Resolute Integrity versus everolimus-eluting Xience Xpedition stents in the management of very long (>30mm) de novo coronary artery stenosis.
Patra S; Chakraborty RN; Pande A; Banerjee S; Jena M; Mandal PC; De SK; Khan A; Das SS; Ghosh D; Nag R
Cardiovasc Revasc Med; 2017; 18(3):160-164. PubMed ID: 28017259
[TBL] [Abstract][Full Text] [Related]
2. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
3. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
4. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
6. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
7. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR).
Kim Y; Oh SS; Jeong MH; Ahn Y; Kim JH; Hong YJ; Sim DS; Kim MC; Kim HS; Yun KH; Oh SK; Kim CJ; Cho MC
Cardiol J; 2019; 26(5):469-476. PubMed ID: 29745969
[TBL] [Abstract][Full Text] [Related]
8. Zotarolimus compared with everolimus eluting stents-angiographic and clinical results after recanalization of true coronary chronic total occlusions.
Markovic S; Lützner M; Rottbauer W; Wöhrle J
Catheter Cardiovasc Interv; 2016 Jul; 88(1):18-23. PubMed ID: 26945903
[TBL] [Abstract][Full Text] [Related]
9. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
11. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial.
Kang DY; Lee CH; Lee PH; Ahn JM; Lee SW; Kim YH; Park SW; Nam CW; Choi YS; Rha SW; Cho JH; Kim W; Her SH; Jeong MH; Yang JY; Lee BK; Park HS; Park DW; Park SJ
Coron Artery Dis; 2019 Jan; 30(1):59-66. PubMed ID: 30507632
[TBL] [Abstract][Full Text] [Related]
13. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
14. Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
Sen H; Lam MK; Tandjung K; Löwik MM; Stoel MG; de Man FH; Louwerenburg JH; van Houwelingen GK; Linssen GC; Doggen CJ; Basalus MW; von Birgelen C
Catheter Cardiovasc Interv; 2015 Jan; 85(1):74-81. PubMed ID: 24585502
[TBL] [Abstract][Full Text] [Related]
15. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
Sen H; Lam MK; Löwik MM; Danse PW; Jessurun GA; van Houwelingen KG; Anthonio RL; Tjon Joe Gin RM; Hautvast RW; Louwerenburg JH; de Man FH; Stoel MG; van der Heijden LC; Linssen GC; IJzerman MJ; Tandjung K; Doggen CJ; von Birgelen C
JACC Cardiovasc Interv; 2015 Jun; 8(7):889-99. PubMed ID: 26003019
[TBL] [Abstract][Full Text] [Related]
16. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
17. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
18. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
[TBL] [Abstract][Full Text] [Related]
19. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
[TBL] [Abstract][Full Text] [Related]
20. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]